Skip to main content
. Author manuscript; available in PMC: 2021 Jan 29.
Published in final edited form as: ACS Appl Mater Interfaces. 2020 Jan 15;12(4):4308–4322. doi: 10.1021/acsami.9b21214

Table 1.

Screening of lipid formulations of MSN/siRNA+miRNA+ICG.

1) Single lipid species
Formulation (-) SPC mDSPE-PEG Chol DPPC DSPC
Stabilization effect (h) 0.1–0.2 6–10 8–12 2–4 0.5–1 0.5–1
2) Two lipids species (w/w, 1:1)
Formulation SPC + mDSPE-PEG SPC + Chol mDSPE-PEG + Chol
Stabilization effect (h) >48 4–6 24–48
3) Ratio of SPC and mDSPE-PEG
Ratio (w/w) 2:1 1:1 1:2
Stabilization effect (h) 24–48 >48 >48
4) Three lipids species (w/w, 2:2:1)c
Formulation SPC + mDSPE-PEG + DSPE-PEG-DBCO SPC + mDSPE-PEG + Chol
Stabilization effect (h) >48 24–48